On this page:OverviewPublicationsKey papers
ScholarIQanswers from OpenAlex & ORCID

Johanna C. Bendell

ResearcherPublications, citations & collaboration network

Johanna C. Bendell is a researcher indexed in ScholarIQ from OpenAlex & ORCID.

How many works does Johanna C. Bendell have?

ScholarIQindexed works

Johanna C. Bendell has 929 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

How many citations does Johanna C. Bendell have?

ScholarIQcitation count

Johanna C. Bendell has 31,109 citations in the OpenAlex counts ScholarIQ stores.

What is the h-index of Johanna C. Bendell?

ScholarIQh-index

Johanna C. Bendell has an h-index of 83 in OpenAlex.

What is the i10-index of Johanna C. Bendell?

ScholarIQi10-index

Johanna C. Bendell has an i10-index of 351 in OpenAlex.

What is the ORCID of Johanna C. Bendell?

ScholarIQorcid

The ORCID for Johanna C. Bendell is on the source record.

What is the OpenAlex record for Johanna C. Bendell?

ScholarIQopenalex

The OpenAlex for Johanna C. Bendell is on the source record.

What are the most-cited papers on Johanna C. Bendell?

ScholarIQmost cited works
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
Michael S. Lee, Baek‐Yeol Ryoo, Chih‐Hung Hsu, Kazushi Numata, Stacey Stein, Wendy Verret, Stephen P. Hack, Jessica Spahn, Bo Liu, Heba Abdullah, Yulei Wang, Aiwu Ruth He, Kyung-Hun Lee, Y-J. Bang, Johanna C. Bendell, Yee Chao, J-S Chen, Hyun Cheol Chung, S. Lindsey Davis, Atul Dev, Edward Gane, Ben George, Aiwu Ruth He, Howard S. Höchster, C-H Hsu, Masafumi Ikeda, Jes Chauviere Lee, M. Lee, Amit Mahipal, Gulam A. Manji, Manabu Morimoto, Kazushi Numata, Michael J. Pishvaian, Shukui Qin, David P. Ryan, B-Y Ryoo, Naoki Sasahira, Stacey Stein, John H. Strickler, N. C. Tebbutt
The Lancet Oncology. 2020569 Citations
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
Jeffrey R. Infante, Leslie A. Fecher, Gerald S. Falchook, Sujatha Nallapareddy, Michael S. Gordon, Carlos Becerra, Douglas J. DeMarini, Donna S. Cox, Yanmei Xu, Shannon R. Morris, Vijay Peddareddigari, Ngocdiep T. Le, Lowell L. Hart, Johanna C. Bendell, Gail Eckhardt, Razelle Kurzrock, Keith T. Flaherty, Howard A. Burris, Wells A. Messersmith
The Lancet Oncology. 2012559 Citations
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
Gerald S. Falchook, Karl D. Lewis, Jeffrey R. Infante, Michael S. Gordon, Nicholas J. Vogelzang, Douglas J. DeMarini, Peng Sun, Christopher Moy, Stephen A. Szabo, Lori Roadcap, Vijay Peddareddigari, Peter F. Lebowitz, Ngocdiep T. Le, Howard A. Burris, Wells A. Messersmith, Peter J. O’Dwyer, Kevin B. Kim, Keith T. Flaherty, Johanna C. Bendell, René González, Razelle Kurzrock, Leslie A. Fecher
The Lancet Oncology. 2012545 CitationsOPEN ACCESS
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial
Charles S. Fuchs, Kohei Shitara, Maria Di Bartolomeo, Sara Lonardi, Salah‐Eddin Al‐Batran, Eric Van Cutsem, David H. Ilson, María Alsina, Ian Chau, Jill Lacy, Michel Ducreux, Guillermo Ariel Mendez, Alejandro Molina Alavez, Daisuke Takahari, Wasat Mansoor, Peter C. Enzinger, Vera Gorbounova, Zev A. Wainberg, Susanna Hegewisch‐Becker, David Ferry, Ji Lin, Roberto Carlesi, Mayukh Das, Manish A. Shah, Alexander Luft, Nina Karaseva, Rubén Dario Kowalyszyn, Carlos Alberto Hernández, Tibor Csőszi, Ferdinando De Vita, Per Pfeiffer, Naotoshi Sugimoto, Judit Kocsis, Andràs Csilla, G. Bodoky, Georgina Garnica Jaliffe, Светлана Проценко, Ayman Madi, Elżbieta Wójcik, Baruch Brenner, Gunnar Folprecht, Tomasz Sarosiek, Katriina Peltola, Peter Bono, Hubert Ayala, Giuseppe Aprile, Cardellino Giovanni Gerardo, Fidel David Huitzil Melendez, Alfredo Falcone, Francesco Di Costanzo, Moustapha Tehfe, Laurent Mineur, Pilar Alfonso, Radka Obermannová, Hélène Senellart, Russell Petty, Leslie Samuel, Péter Ács, Maen Hussein, M. Nechaeva, Frans Erdkamp, Elizabeth Won, Johanna C. Bendell, Javier Gállego, Sylvie Lorenzen, Bohuslav Melichar, Miguel Angel Escudero, Denis Pezet, Jean–Marc Phelip, Diego Kaen, James A. Reeves, Federico Longo Muñoz, Srinivasan Madhusudan, Carlo Barone, Luis Fein, Ángel Gómez Villanueva, Mohamed Hebbar, Jana Prausová, L. Visa Turmo, J. Vidal Barrull, Mette Yilmaz, Alex Beny, Hanneke W.M. van Laarhoven, Brian DiCarlo, Taito Esaki, Kazumasa Fujitani, Karen Geboes, Ravit Geva, Shigenori Kadowaki, Stephen Leong, Nozomu Machida, Moses S. Raj, Francisco Javier Ramírez Godinez, Ágnes Ruzsa, Hugo Ford, William Lawler, Nicolas Robert Maisey, Jiřı́ Petera, Einat Shacham‐Shmueli, Isabelle Sinapi
The Lancet Oncology. 2019285 CitationsOPEN ACCESS
Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial
Roy S. Herbst, Hendrik‐Tobias Arkenau, Rafael Santana-Dávila, Emiliano Calvo, Luis Paz‐Ares, Philippe A. Cassier, Johanna C. Bendell, Nicolas Penel, Matthew Krebs, Juan Martín-Liberal, Nicolás Isambert, A. Segado Soriano, Martin Wermke, Jennifer L. Cultrera, Ling Gao, Ryan C. Widau, Gu Mi, Jin Jin, David Ferry, Charles S. Fuchs, Daniel P. Petrylak, Ian Chau
The Lancet Oncology. 2019275 CitationsOPEN ACCESS

Related on ScholarIQ

470M+ articles · free account